Lindynette

Ethinylestradiol and Gestodene, the active ingredients in Lindynette, are a combined oral contraceptive presented as tablets for oral use. They prevent pregnancy by inhibiting ovulation, thickening cervical mucus, and inducing endometrial changes in women of reproductive age. The tablet contains a low‑dose estrogen component combined with a progestogenic agent, offering a favorable bleeding profile and cycle control.

GNH USA supplies Lindynette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lindynette, a combined oral contraceptive, is used to prevent pregnancy by modulating the hormonal regulation of the menstrual cycle. - Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential. - Cycle regulation: helps achieve more predictable menstrual bleeding patterns and may reduce dysmenorrhea. - Management of ovarian cysts: can suppress the development of functional ovarian cysts in women with recurrent cyst formation.

Lindynette may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Breast tenderness: discomfort or swelling of breast tissue. - Headache: occasional tension‑type or migraine‑like pain. - Breakthrough bleeding: spotting between periods, especially during early cycles. - Weight fluctuation: mild fluid retention or appetite changes. - Mood changes: irritability or mild depressive symptoms.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism, requiring immediate medical attention. - Arterial thrombosis: stroke or myocardial infarction, particularly in high‑risk individuals. - Severe hypertension: sudden increase in blood pressure that may be life‑threatening. - Hepatic adenoma: benign liver tumor associated with prolonged estrogen exposure. - Anaphylaxis: rare severe allergic reaction with rash, swelling, and respiratory distress. - Visual disturbances: sudden loss of vision or eye pain, indicating possible vascular events.

Before prescribing Lindynette, clinicians should evaluate individual risk factors and contraindications. - Pregnancy contraindication: do not use in women who are or may become pregnant. - Smoking restriction: avoid in women over 35 who smoke more than 15 cigarettes per day. - Thromboembolic history: contraindicated in patients with past deep vein thrombosis, pulmonary embolism, or stroke. - Liver disease: avoid in active liver disease or hepatic tumors. - Hypertension: monitor and control blood pressure before initiating therapy. - Store at ambient temperature: keep tablets in the original packaging, protect from moisture and direct sunlight.

Lindynette can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampicin, phenytoin, carbamazepine): may reduce contraceptive efficacy. - Antifungal agents (e.g., ketoconazole, itraconazole): can increase hormone levels and risk of side effects. - HIV protease inhibitors (e.g., ritonavir): may affect hormone metabolism.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may slightly increase plasma hormone concentrations. - Antihypertensive drugs: combined use may require blood pressure monitoring. - Antidiabetic agents: hormonal changes can affect glucose control, necessitating dose adjustments.